Final OS and the Exploratory Analysis of the Outcome with Osimertinib Up-Front versus the Sequential Approach in Patients with Advanced EGFR-mutated NSCLC
Findings from the EORTC LCG-163 APPLE study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
EMA Recommends Granting Marketing Authorisation for Efbemalenograstim Alfa
It is intended to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy
Safety and Preliminary Signs of Activity of OMO-103, a MYC Inhibitor, in Allcomers Solid Tumours
Findings from a dose-escalation phase I study
Staging at Presentation for Patients with Localised Pancreatic Ductal Adenocarcinoma Should Be Based on Anatomy, CA 19-9, and Performance Status
Findings from the Trans-Atlantic Pancreatic Surgery Consortium study
A New Online Tool Predicts RFS and OS Probabilities in Patients with Stage II Melanoma
MIA calculator should help inform clinicians on which patients to select for adjuvant therapy
EMA Recommends Extension of Indications for Idecabtagene Vicleucel
It concerns the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies
Sacituzumab Govitecan Plus Pembrolizumab Demonstrate Encouraging Activity in Patients with mUC Who Progress after Platinum-Based Chemotherapy
Findings from the TROPHY-U-01 cohort 3 study
FDA Approves Erdafitinib for Locally Advanced or Metastatic Urothelial Carcinoma
Evidence for efficacy is based on the results from a Cohort 1 of the Study BLC3001
Complete Cancer Prevalence in Europe in 2020 Reveals an Increased Proportion of Cancer Survivors Beyond 5 Years from Diagnosis
Findings from the EUROCARE-6
EMA Recommends Extension of Therapeutic Indications for Selpercatinib
New indication concerns the treatment of adults and adolescents with RET fusion-positive thyroid cancer that is radioactive iodine-refractory
Genomic and Immunophenotypic Heterogeneity of Acquired Resistance to Immune Checkpoint Inhibitors in NSCLC
Findings from a comprehensive genomic profiling and immunophenotypic characterisation
Development of Secondary T-Cell Cancers After the Use of CAR T-Cells for the Treatment of Relapsed or Refractory Haematologic Malignancies
In few cases for which genetic sequencing has been performed to date, the CAR transgene has been detected in the malignant clone